AR-WESTROCK-COFFEE
17.12.2021 02:47:14 CET | Business Wire | Press release
Westrock Coffee Company, LLC (Westrock Coffee) announced plans today to expand its operations and beverage capabilities with the purchase of a new facility in Conway, Arkansas that, when fully built-out, will be the largest facility of its type in the United States. Westrock Coffee will also expand its extracts manufacturing capacity in Concord, North Carolina, and launch new operations in Malaysia that will serve its rapidly growing customer demand across the Asia-Pacific (APAC) and Middle East and North Africa (MENA) regions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006195/en/
“We are expanding our finished product offerings, adding end beverage packaging solutions, and expanding our geographic reach to meet our growing customer demand,” said Scott Ford, CEO and co-founder of Westrock Coffee. “Our growth benefits everyone at Westrock Coffee — from our global customers and farmer partners to our current and future employees and the communities where they live. These facility expansion announcements provide further evidence that we are well on our way to accomplishing our mission of building and efficiently operating the preeminent integrated coffee, tea, and extract supply chain in the world in order to enhance the lives of our farmer partners and fuel the success of the customers that we serve.”
“Westrock Coffee Company provides the drink that fuels many Arkansans in the workplace, and others all around the world,” Arkansas Governor Asa Hutchinson said. “The expansion into Conway by repurposing this facility and providing new jobs reflects the growth of Westrock and the fact that Arkansas is a dynamic and welcoming place to do business.”
New Facility in Conway, Arkansas
The company finalized the purchase of a 524,000 square-foot facility in Conway, Arkansas that will provide Westrock Coffee ample space for the development, production, and distribution of its coffee, tea, and ready-to-drink (RTD) products. The location will utilize state-of-the-art equipment, including advanced robotics, specifically designed to efficiently manufacture and package a wide range of beverages, such as canned or bottled cold brew coffees, lattes, assorted teas, and juice-based products as well as single serve coffee cups. The space will also incorporate state-of-the-art quality assurance and product development labs, enabling Westrock Coffee to create, test, and produce new beverage solutions.
“From skilled labor to our business climate, Arkansas has the tools in place to help businesses grow and prosper,” Arkansas Secretary of Commerce Mike Preston said. “We are proud of our homegrown success stories like Westrock Coffee. By implementing a unique business model, Westrock has improved the lives of farmers, employees, and communities at every step in its supply chain. We at AEDC are excited to watch them enter this new phase of development.”
The new Conway location will require a variety of skilled jobs to support our focus on global product innovation, manufacturing, and packaging. Initially, up to 50 new jobs will be created following phase one of the build out, which is expected to be completed in the first quarter of 2023, then growing to approximately 250 positions over time. Many of the jobs needed to operate the facility will require a significantly advanced and skilled workforce, commanding higher salaries, ranging up to over $100,000 per year.
Conway will be an addition to the company's already established presence in Arkansas which has corporate offices in Little Rock and a manufacturing facility in North Little Rock.
“Westrock Coffee and Conway will be an exceptional partnership. I am delighted to welcome them to our community. The city is fortunate to have Westrock Coffee bring its global presence, outlook, and commitment to investing in the lives of their partners throughout the world,” said Bart Castleberry, mayor of Conway. “I look forward to Westrock continuing their success in Conway and abroad for years to come. I would like to thank not only Westrock Coffee but also the Conway Area Chamber of Commerce for their commitment to Conway.”
Upgrades in Concord, North Carolina
In addition, the company announced it is expanding its Commercial Park location in Concord, North Carolina. The expansion of this leading extract manufacturing facility will allow Westrock Coffee to respond to unprecedented growth due to burgeoning customer demand for its extract, tea, and herbal products. The expansion will add two fully automated production lines, which will increase overall capacity of extracts processing at this facility by over fifty percent. The expansion will also include modernizing its current manufacturing and packaging process for bottled products. Upgrades to the Concord facility should be complete by the end of 2022.
“We have seen strong product demand and customer growth over the past year and our expansion puts us at the forefront of providing beverage solutions for any type of business in any form of finished packaging. This progress is a testament to every person who plays a role in our day-to-day operations,” said Ford.
Addition in Johor Bahru, Malaysia
Work is already complete on the 90,000 square-foot, two-building facility in Johor Bahru, Malaysia announced earlier this year, with finished good production set to begin in the first quarter of 2022. The new facility, which is just 30 minutes from the international hub of Singapore, will enhance Westrock Coffee’s roasting capacity to accommodate for increases in manufacturing, packaging, and warehousing, of coffee and extract solutions across APAC and MENA regions. While Westrock Coffee has a history in international coffee trade and export, this will be its first roasting, manufacturing, and packaging facility outside of the U.S.
About Westrock Coffee Company
Westrock Coffee Company, LLC is the leading integrated coffee, tea, and extract service provider in the U.S., providing coffee sourcing and financing, supply chain management, product development, roasting, packaging, and distribution services to retailers, restaurants, convenience stores, commercial accounts, and hospitality customers around the world. With offices in 10 countries, the company sources coffee and tea from 35 origin countries and provides service under both the Westrock Coffee and S&D Coffee & Tea brands.
About Arkansas Economic Development Commission
The Arkansas Economic Development Commission (AEDC), a division of the Arkansas Department of Commerce, seeks to create economic opportunity by attracting higher-paying jobs, expanding, and diversifying local economies in the state, increasing incomes and investment, and generating growth throughout The Natural State. Arkansas is a pro-business environment operating leaner, faster and more focused through a streamlined state government designed to act on corporate interests quickly and decisively. For more information, visit www.ArkansasEDC.com . The Arkansas Department of Commerce is the umbrella department for workforce and economic development drivers. Its divisions and regulatory boards include Division of Aeronautics, Waterways Commission, Wine Producers Council, Division of Workforce Services, Office of Skills Development, State Bank Department, Insurance Department, Securities Department, Economic Development Commission and Development Finance Authority. It was established July 2019 as part of Governor Asa Hutchinson’s wide-sweeping efficiency and transformation efforts to reduce 42 cabinet agencies to 15 while maintaining services for all Arkansans.
Westrock Conway Facility Press Reel:
https://drive.google.com/file/d/1xdNJmARFYNNyyZYzdngiCm6k6WCu99fE/view?usp=sharing
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216006195/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
